| __timestamp | Supernus Pharmaceuticals, Inc. | Telix Pharmaceuticals Limited |
|---|---|---|
| Wednesday, January 1, 2014 | 5758000 | 22622695 |
| Thursday, January 1, 2015 | 8423000 | 24863028 |
| Friday, January 1, 2016 | 11986000 | 21351001 |
| Sunday, January 1, 2017 | 15215000 | 53837297 |
| Monday, January 1, 2018 | 15356000 | 16080096 |
| Tuesday, January 1, 2019 | 16660000 | 18525736 |
| Wednesday, January 1, 2020 | 52459000 | 2024000 |
| Friday, January 1, 2021 | 75061000 | 2548000 |
| Saturday, January 1, 2022 | 87221000 | 61556000 |
| Sunday, January 1, 2023 | 83779000 | 188157000 |
Unlocking the unknown
In the dynamic world of pharmaceuticals, understanding cost structures is crucial. Over the past decade, Telix Pharmaceuticals Limited and Supernus Pharmaceuticals, Inc. have shown distinct trends in their cost of revenue. From 2014 to 2023, Supernus Pharmaceuticals experienced a steady increase, peaking in 2022 with a 1,414% rise from 2014. Meanwhile, Telix Pharmaceuticals saw a more volatile pattern, with a significant surge in 2023, marking an 832% increase from its 2014 figures. This fluctuation highlights Telix's strategic shifts and market adaptations. The data underscores the importance of cost management in maintaining competitive advantage and profitability in the pharmaceutical sector. As these companies navigate the complexities of the industry, their cost of revenue trends offer valuable insights into their operational strategies and market positioning.
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and Telix Pharmaceuticals Limited's Expenses
Cost of Revenue Trends: Regeneron Pharmaceuticals, Inc. vs Supernus Pharmaceuticals, Inc.
Cost of Revenue Comparison: Takeda Pharmaceutical Company Limited vs Telix Pharmaceuticals Limited
Biogen Inc. vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Incyte Corporation and Telix Pharmaceuticals Limited's Expenses
Analyzing Cost of Revenue: Pharming Group N.V. and Telix Pharmaceuticals Limited
Cost Insights: Breaking Down Lantheus Holdings, Inc. and Supernus Pharmaceuticals, Inc.'s Expenses
Cost of Revenue: Key Insights for Telix Pharmaceuticals Limited and Alkermes plc
Cost Insights: Breaking Down Telix Pharmaceuticals Limited and Perrigo Company plc's Expenses
Cost of Revenue Trends: ADMA Biologics, Inc. vs Supernus Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc. vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Supernus Pharmaceuticals, Inc. and Xencor, Inc.